STSA Stock Overview
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines.
Satsuma Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.00|
|52 Week High||US$8.08|
|52 Week Low||US$2.51|
|1 Month Change||-6.83%|
|3 Month Change||38.89%|
|1 Year Change||32.16%|
|3 Year Change||-46.67%|
|5 Year Change||n/a|
|Change since IPO||-64.50%|
Recent News & Updates
Will Satsuma Pharmaceuticals (NASDAQ:STSA) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Here's Why We're Watching Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|STSA||US Pharmaceuticals||US Market|
Return vs Industry: STSA exceeded the US Pharmaceuticals industry which returned 5.2% over the past year.
Return vs Market: STSA exceeded the US Market which returned -21.5% over the past year.
|STSA Average Weekly Movement||12.7%|
|Pharmaceuticals Industry Average Movement||11.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: STSA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: STSA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company’s lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Satsuma Pharmaceuticals Fundamentals Summary
|STSA fundamental statistics|
Is STSA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|STSA income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.92|
|Net Profit Margin||0.00%|
How did STSA perform over the long term?See historical performance and comparison
Is STSA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for STSA?
Other financial metrics that can be useful for relative valuation.
|What is STSA's n/a Ratio?|
Price to Book Ratio vs Peers
How does STSA's PB Ratio compare to its peers?
|STSA PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
THRX Theseus Pharmaceuticals
MIST Milestone Pharmaceuticals
RVLP RVL Pharmaceuticals
STSA Satsuma Pharmaceuticals
Price-To-Book vs Peers: STSA is expensive based on its Price-To-Book Ratio (2.6x) compared to the peer average (2x).
Price to Earnings Ratio vs Industry
How does STSA's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: STSA is expensive based on its Price-To-Book Ratio (2.6x) compared to the US Pharmaceuticals industry average (1.7x)
Price to Book Ratio vs Fair Ratio
What is STSA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||2.6x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate STSA's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of STSA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate STSA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate STSA's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Satsuma Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STSA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: STSA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: STSA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: STSA is forecast to have no revenue next year.
High Growth Revenue: STSA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if STSA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Satsuma Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: STSA is currently unprofitable.
Growing Profit Margin: STSA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: STSA is unprofitable, and losses have increased over the past 5 years at a rate of 39.7% per year.
Accelerating Growth: Unable to compare STSA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STSA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).
Return on Equity
High ROE: STSA has a negative Return on Equity (-84.04%), as it is currently unprofitable.
Discover strong past performing companies
How is Satsuma Pharmaceuticals's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: STSA's short term assets ($72.5M) exceed its short term liabilities ($7.9M).
Long Term Liabilities: STSA's short term assets ($72.5M) exceed its long term liabilities ($70.0K).
Debt to Equity History and Analysis
Debt Level: STSA is debt free.
Reducing Debt: STSA had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: STSA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: STSA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 34.8% each year
Discover healthy companies
What is Satsuma Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Satsuma Pharmaceuticals Dividend Yield vs Market|
|Company (Satsuma Pharmaceuticals)||n/a|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Pharmaceuticals)||2.6%|
|Analyst forecast in 3 Years (Satsuma Pharmaceuticals)||n/a|
Notable Dividend: Unable to evaluate STSA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate STSA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if STSA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if STSA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as STSA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Kollins (59 yo)
Mr. John A. Kollins, MBA, has been Director, President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc since July 2016. He served as Chief Business Officer and Senior Vice President of Transcep...
CEO Compensation Analysis
|John Kollins's Compensation vs Satsuma Pharmaceuticals Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$830k||US$500k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$4m||US$456k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$1m||US$391k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$568k||US$362k|
Compensation vs Market: John's total compensation ($USD830.00K) is below average for companies of similar size in the US market ($USD1.72M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Experienced Management: STSA's management team is seasoned and experienced (5.2 years average tenure).
Experienced Board: STSA's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|24 Nov 21||BuyUS$15,837||Commodore Capital LP||Company||2,922||US$5.42|
|22 Nov 21||BuyUS$72,329||Commodore Capital LP||Company||13,204||US$5.49|
|11 Nov 21||BuyUS$104,332||Commodore Capital LP||Company||17,563||US$6.05|
|08 Nov 21||BuyUS$3,354||Commodore Capital LP||Company||560||US$5.99|
|05 Nov 21||BuyUS$54,642||Commodore Capital LP||Company||9,200||US$5.95|
|02 Nov 21||BuyUS$50,083||Commodore Capital LP||Company||8,880||US$5.64|
|29 Oct 21||BuyUS$254,957||Commodore Capital LP||Company||44,651||US$5.71|
|28 Oct 21||BuyUS$299,422||Commodore Capital LP||Company||54,663||US$5.55|
|22 Oct 21||BuyUS$329,442||Commodore Capital LP||Company||60,445||US$5.51|
|20 Oct 21||BuyUS$665,237||Commodore Capital LP||Company||128,243||US$5.44|
|18 Oct 21||BuyUS$784,845||Commodore Capital LP||Company||162,194||US$4.87|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Satsuma Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Satsuma Pharmaceuticals, Inc.
- Ticker: STSA
- Exchange: NasdaqGM
- Founded: 2016
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$189.525m
- Shares outstanding: 31.59m
- Website: https://www.satsumarx.com
Number of Employees
- Satsuma Pharmaceuticals, Inc.
- 400 Oyster Point Boulevard
- Suite 221
- South San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|STSA||NasdaqGM (Nasdaq Global Market)||Yes||Common Shares||US||USD||Sep 2019|
|1LV||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Sep 2019|
|1LV||MUN (Boerse Muenchen)||Yes||Common Shares||DE||EUR||Sep 2019|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/30 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.